+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using PLXNA1 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using PLXNA1 mouse mAb (green) and negative control (red).    

  
  

The PLXNA1 antibody targets plexin A1 (PLXNA1), a transmembrane receptor belonging to the plexin family, which plays critical roles in cell signaling and communication. PLXNA1 primarily interacts with semaphorin ligands, mediating diverse biological processes such as axon guidance, cell migration, immune regulation, and angiogenesis. Structurally, it contains a large extracellular domain for ligand binding, a transmembrane region, and a cytoplasmic domain that transmits intracellular signals via Rho GTPases and other downstream effectors. Dysregulation of PLXNA1 has been implicated in neurological disorders, cancer progression, and vascular abnormalities.

PLXNA1 antibodies are essential tools for studying its expression, localization, and function in physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect PLXNA1 in tissues or cultured cells. Monoclonal antibodies offer high specificity, while polyclonal antibodies may detect multiple epitopes, enhancing sensitivity. Researchers also utilize PLXNA1 antibodies to explore its role in tumorigenesis, metastasis, and neural circuit formation, particularly in cancers (e.g., breast, prostate) where PLXNA1 overexpression correlates with poor prognosis.

Challenges include ensuring antibody specificity due to homology among plexin family members. Validation via knockout controls or siRNA knockdown is critical. Despite these hurdles, well-validated PLXNA1 antibodies remain indispensable for unraveling its complex signaling networks and therapeutic potential in disease models.